New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:43 EDTRTRXBroadfin Capital reports 6.93% passive stake in Retrophin
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
15:30 EDTRTRXRetrophin founder Shkreli selling stake to fund new company, Feuerstein says
Martin Shkreli, the founder and former CEO of Retrophin, is selling his stake in the company as he tries to raise $50M of funding for a new company, Turing Pharma, reported TheStreet's Adam Feuerstein, citing sources. Reference Link
November 17, 2014
08:06 EDTRTRXRetrophin names Laura Clague as CFO
Subscribe for More Information
November 13, 2014
18:40 EDTRTRXOn The Fly: After Hours Movers
UP AFTER EARNINGS: TubeMogul (TUBE), up 12.4%... Weibo (WB), up 3.2%... Nordstrom (JWN), up 3.1%. ALSO HIGHER: Geron (GERN), up 30.7% after announcing a global strategic collaboration with Janssen Biotech... Baker Hughes (BHI), up 16.2% following reports that the company is in talks to be acquired by Halliburton (HAL)... Halliburton is up 1.4%... Pandora (P), up 4% after announcing a conference call to discuss Web IV proceeding... AmerisourceBergen (ABC), up 1.1% after being awarded a $4.06B government contract. DOWN AFTER EARNINGS: Retrophin (RTRX), down 6.6%... Phoenix New Media (FENG), down 8.4%... Voxeljet AG (VJET), down 8.6%... Intrexon (XON), down 1.1%... Youku Tudou (YOKU), down 5.7%... Applied Materials (AMAT), down 2.5%. ALSO LOWER: Puma Biotechnology (PBYI), down 6.9% following PB272 Phase II Trial results... EnLink Midstream (ENLK), down 4.8% after filing to sell 10.5M common units representing limited partners.
17:19 EDTRTRXRetrophin lowers FY14 revenue view to $26M-$29M from $30M-$35M
Based on the slower than expected progress while initially bringing patients back on Thiola after the supply outage, Retrophin is revising its 2014 financial guidance. The company now expects full-year 2014 revenues to be between $26M and $29M, down from the previously listed range of $30M to $35M. The company is removing the previously stated 2015 financial guidance and will be providing new 2015 financial guidance when year-end financial results are reported, which will be its new standard of practice.
17:16 EDTRTRXRetrophin reports Q3 EPS (53c) vs (20c) last year
Net sales for the third quarter of 2014 were $8.3M from product sales of Chenodal, Thiola and Vecamyl. Retrophin reported no revenue for the third quarter of 2013.
November 10, 2014
16:39 EDTRTRXRetrophin names Stephen Aselage as CEO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use